NCT00708214View on ClinicalTrials.gov

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

February 28, 2010

Conditions
Breast Neoplasms
Interventions
DRUG

BIBW 2992

BIBW 2992 at high and medium dosages

DRUG

BIBW 2992

BIBW 2992 at high and medium dosages

DRUG

Letrozole

Letrozole at standard dosage

DRUG

Letrozole

Letrozole at standard dosage

Trial Locations (5)

Unknown

1200.5.3306A Boehringer Ingelheim Investigational Site, Caen

1200.5.3304A Boehringer Ingelheim Investigational Site, Nice

1200.5.3301A Boehringer Ingelheim Investigational Site, Paris

1200.5.3305A Boehringer Ingelheim Investigational Site, Paris

1200.5.3302A Boehringer Ingelheim Investigational Site, Saint-Cloud

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00708214 - BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter